Chihuahua City

The trials here

What the 28 trials at this site are about, from their registry records.

Conditions

• COPD6 trials
• Asthma5 trials
• Chronic kidney disease3 trials
• Idiopathic pulmonary fibrosis3 trials
• Lung cancer3 trials
• Lupus (SLE)2 trials
• Atrial fibrillation1 trial
• Diffuse large B-cell lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Rheumatoid arthritis1 trial
• and 3 more

Phase

• Phase 322 trials
• Phase 26 trials

Status

• Active, not recruiting10 trials
• Recruiting7 trials
• Completed6 trials
• Not yet recruiting3 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• AstraZeneca25 trials
• Endeavor Biomedicines, Inc.2 trials
• Acerta Pharma BV1 trial

Running trials

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Active, not recruiting

  Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

  NCT06473779· Phase 3· AstraZeneca· Source

• Recruiting

  Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

  NCT06307665· Phase 3· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

  NCT05925803· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

  NCT06023589· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

  NCT05211895· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

  NCT05138133· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

  NCT04550260· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

  NCT04529772· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

  NCT03775486· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• Asthma2 recruiting
• COPD2 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· Phase 3· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· Phase 3· AstraZeneca· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

  NCT05274815· Phase 3· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Completed

  A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT04968574· Phase 2· Endeavor Biomedicines, Inc.· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source